DCM
NPCE icon

Driehaus Capital Management’s Neuropace NPCE Stock Holding History

Driehaus Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Sell
1,447,391
-4,220
-0.3% -$67.9K 0.13% 212
2026
Q1 		$19.1M Sell
1,451,611
-59,678
-4% -$895K 0.14% 209
2025
Q4 		$23.3M Buy
1,511,289
+571,770
+61% +$7.65M 0.16% 185
2025
Q3 		$9.69M Sell
939,519
-65,839
-7% -$621K 0.07% 282
2025
Q2 		$11.2M Buy
1,005,358
+201,918
+25% +$2.52M 0.09% 242
2025
Q1 		$9.87M Buy
+803,440
New +$10.1M 0.1% 249

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Driehaus Capital Management's NPCE Position: Q2 2026 in Review

Driehaus Capital Management reduced its Neuropace (NPCE) stake by 0.29% in Q2 2026, selling an estimated $67.9K and leaving 1,447,391 shares worth $23M. The position accounts for 0.13% of the portfolio, ranked #212.

Driehaus Capital Management first reported a position in NPCE in Q1 2025 and has held it in 6 quarters since. The position peaked at $23.3M in Q4 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Driehaus Capital Management held 1,447,391 shares of Neuropace worth $23M as of Q2 2026.
  • Driehaus Capital Management sold 4,220 Neuropace shares in Q2 2026, an estimated $67.9K.
  • Neuropace made up 0.13% of Driehaus Capital Management's portfolio in Q2 2026, its #212 holding.
  • Driehaus Capital Management first reported a position in Neuropace in Q1 2025 and has held it in 6 quarters since.
  • Driehaus Capital Management's Neuropace position peaked at $23.3M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.